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Abstract
Background
Identification of risk factors for venous thromboembolism (VTE) is of utmost importance to
improve current prophylactic regimes and treatment guidelines. The extent to which a family
history contributes to the risk of VTE needs further exploration.
Objectives
To examine the relative rate of VTE in first-degree relatives compared with the general
population.
Methods
By crosslinking Danish nationwide registries we identified patients with VTE between 1978
and 2012, and their familial relations. The first member in a family to acquire VTE was
defined as the proband. All first-degree relatives to probands were followed from the VTE
date of the proband and until an event (VTE), death, emigration, 100 year birthday or end of
study: 31st of December 2012, whichever came first. The relative rate of VTE was estimated
by standardized incidence ratios (SIR) using time-dependent Poisson regression models,
with the general population as a fixed reference.
Results
We identified 70,767 children of maternal probands, 66,065 children of paternal probands,
and 29,183 siblings to sibling probands. Having a maternal proband or a paternal proband
were associated with a significantly increased VTE rate of 2.15 (CI: 2.00–2.30) and 2.06 (CI:
1.92–2.21), respectively. The highest estimate of VTE was observed among siblings
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(adjusted SIR of 2.60 [CI: 2.38–2.83]). Noteworthy, the rate of VTE increased for all first-
degree relatives when the proband was diagnosed with VTE in a young age ( 50 years).
Conclusion
A family history of VTE was associated with a significantly increased rate of VTE among
first-degree relatives compared with the general population.
Introduction
Venous thromboembolism (VTE), i.e. deep venous thrombosis (DVT) and pulmonary embo-
lism (PE), poses a great burden for both patients and healthcare systems worldwide. [1–3]
VTE affects 1–2 out of 1,000 individuals each year, and is associated with a high risk of mor-
bidity and mortality. [1–6] VTE is a multifactorial disease, possibly caused by an interim of
both genetic and environmental risk factors. [7, 8] Genetic risk factors for VTE have been rec-
ognized since the 1960s when the antithrombin deficiency was first discovered. [9, 10] As of
today, several genetic risk factors have been identified including; factor V Leiden, protein C
and, protein S deficiency. [10–13] However, from genetic variation studies, common polymor-
phisms have been found to only account for 5% of VTE heritability. [9, 14, 15] VTE tend to
cluster in families and known thrombophilia’s does not fully explain the increased risk in these
individuals. [16, 17] Previous studies have observed an increased risk of VTE among first-
degree relatives [17–30] and have revealed that a family history of VTE is an independent risk
factor irrespective of known thrombophilia.[17] However, some of these studies were limited
by investigating the risk in subpopulations, by their sample size, and by using questionnaires.
[23–29] In addition, the studies have been limited by only examining the risk of VTE in either,
siblings [20, 21] or parents. [19] In the search for potential genetic risk factors, it is important
to characterize the familial risk of VTE in detail. Furthermore, identification of VTE risk fac-
tors and thereby high-risk patients is essential to improve primary prophylactic regimes and
treatment guidelines. Thus the aim of this study was to provide a thorough description of the
risk of VTE among first-degree relatives according to probandship and according to the age at
diagnosis of the proband.
Methods
Data sources
In this cohort study, we used the Danish nationwide administrative registries, from which it is
possible to obtain information on all hospital contacts, all prescribed medicines from pharma-
cies, and date of birth etc. [31–34] All Danish residents are at birth or migration given a unique
identification number, which enables cross linkage between the nationwide Danish registries
on an individual level. [31] Information from the Danish National Patient Register includes all
in-patients hospital contacts from 1978 and onward, with out-patient and emergency depart-
ment visits registered from 1995 and onwards. [32] All diagnoses are registered according to
the International Classification of Diseases (ICD) and are classified as either a primary or sec-
ondary diagnosis. Before 1994 diagnoses were registered according to the 8th version and after
1994 according to the 10th version. [32] From the Danish National Prescription Registry, infor-
mation on all prescribed dispensed medicines can be obtained from 1995 and onward. [33]
The Danish Civil Registration system provides information on date of birth, date of death, sex,
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emigration and immigration. The Danish Fertility Registry, has since 1954, collected informa-
tion on familial relations, making it possible to obtain information on parents, children, and
siblings.
Study population
By cross-linking the Danish National Patient Registry with the Civil Registration System, all
patients (inpatients and outpatients) in the period of 1978–2012 with a primary or second-
ary discharge diagnosis of VTE were identified. Through the Danish Fertility Registry
familial relations were identified, parents with VTE or the first sibling in a sib-ship with
VTE were defined as the proband. First-degree relatives to probands (children of maternal
probands, children of paternal probands, and sibling-to-sibling probands) were followed
from the probands’ date of VTE, date of birth or immigration whichever came first, and
until 100 years of age, emigration, developing VTE, death, or 31st of December 2012. We
excluded patients who died before 1st of January 1978, stillborn babies, and adopted chil-
dren. It was possible for the first-degree relatives to be classified in more than one group,
meaning that i.e. a child of a maternal proband could also be classified as a sibling to a sib-
ling proband.
Covariates
Comorbidities. Information regarding comorbidities was achieved from the National
Patient Register (ICD- 8 and ICD-10 diagnose codes). These included; stroke, myocardial
infarction, atrial fibrillation, ischemic heart disease, vascular disease, chronic heart failure, can-
cer, chronic kidney disease, liver disease, and chronic obstructive pulmonary disease. The
diagnosis of hypertension and diabetes was defined from a diagnosis or from the use of either
anti-diabetic drugs or antihypertensive medication (S1 Table).
Concomitant medication. Baseline pharmacotherapy of included patients was examined
using the Danish Register of Medicinal Product Statistics and included: ADP-inhibitors, cal-
cium antagonists, beta-blockers, diuretics, renin- angiotensin inhibitors, ACE-inhibitors, non-
steroidal anti-inflammatory drugs, lipid modifying agents, ulcer medication, antipsychotics,
oral anticoagulation therapy, and heparin (S2 Table).
Statistical analyses
The absolute risk of VTE among first-degree relatives was examined by crude cumulative inci-
dence curves taking into account the competing risk of death. The relative risk of VTE among
first-degree relatives was estimated by Poisson regression modeling, where the general popula-
tion was used as a fixed reference, as has been performed previously.[35, 36] Two Poisson
models were constructed; the first model was adjusted for age, sex, and calendar year and the
second model was adjusted for age, sex, calendar year, and the aforementioned comorbidities
and concomitant medication. All variables were entered as time dependent variables, making
it possible to update; calendar year, age, comorbidities, and concomitant pharmacotherapy
continuously every 5 years. [35, 36] Results were shown as standardized incidence ratios with
95% confidence intervals (CI). Interaction was examined using an interaction term in the
model, and if significant the analyses were stratified where appropriate. All statistical analyses
were performed at a 0.05 significance level. Handling of data and statistical analysis was per-
formed using SAS (Statistical Analytical System, version 9.4, SAS Institute, Gary, NC.) and R
(version 3.0.2 for Windows, R Foundation for Statistical Computing).
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Subgroup and sensitivity analyses
All first-degree relatives to probands were subdivided according to age of diagnoses of the pro-
band;< 30, 30–49, 50–59, 60–69, and 70 years of age, and in supplementary analyses,
into 50 and>50 years of age at diagnosis of the proband. To evaluate a potential familial
aggregation of VTE, we examined the rate of the condition in individuals having one or more
probands previously diagnosed with VTE. Furthermore, an analysis on the risk of VTE among
spouses was performed, in order to investigate the influence of potential environmental risk
factors. The first spouse in the marriage to be diagnosed with VTE was defined as the proband.
An additional sensitivity analysis was performed, where the risk of VTE was investigated in
adopted children of mothers and fathers with VTE.
Ethics
Retrospective registry-based studies do not require approval from the Research Ethics Com-
mittee System. The Danish Data Protection Agency had approved use of data for this study
(ref.no: 2007-58-0015 / GEH-2014-012 I-Suite no: 02720).
Results
From 1978 to 2012, a cumulative number of 9,102,927 Danish residents were identified (Fig
1). Of these 108,636 patients were admitted with a first-time VTE and from these patients,
38,862 patients were identified as maternal probands, 35,355 were identified as paternal pro-
bands and 18,156 were identified as sibling probands. A total of 166,615 first-degree relatives
to probands were identified, of which: 70,767 were children of maternal probands, 66,065 were
children of paternal probands, and 29,183 were sibling-to-sibling probands. Because the first-
degree relatives could be classified in more than one group, 160,615 first-degree relatives were
identified, when combining children of maternal and paternal proband and siblings to sibling
probands.
Baseline characteristics of probands and first-degree relatives are presented in Tables 1 and
2, respectively. The median age was higher among paternal and maternal probands than
among sibling probands. Approximately 70% of the probands had DVT and 30% had PE as
index event. The maternal and paternal probands had more comorbidity and used more con-
comitant medication than the sibling probands. The most present comorbidity was hyperten-
sion, diabetes, and cancer.
Table 2 shows the baseline characteristics of the children of maternal and paternal probands
along with sibling-to-sibling probands. The first-degree relatives had less comorbidity and
used less concomitant medication than their probands, mainly due to the lower age at inclu-
sion in to the study.
Risk of VTE
All first-degree relatives were followed for a median time of 5.8 years [inter quartile range
(IQR): 2.6–9.8]. In this time period, 1,983 developed VTE at a median age of 42 [IQR: 34–49].
Children of maternal probands were followed for a median time of 5.95 years [IQR: 2.6–10.4],
and 823 developed VTE at a median age of 44 [IQR: 36–50] years. Children of paternal pro-
bands were followed for 6.7 years [IQR: 3.3–10.4], and 769 developed VTE at a median age of
41 [IQR: 33–48] years. Of the sibling-to-sibling probands, 517 developed VTE at a median age
of 43 [IQR: 36–49] years during a median time of follow-up of 4.8 [IQR: 1.9–8.7] years. The
Danish general population was followed for a median time of 25.0 years [IQR: 10.8–35.0] and
developed VTE at a median age of 67 [IQR: 52–78].
Familial Clustering of Venous Thromboembolism
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Fig 2 shows the cumulative incidence of VTE among first-degree relatives. At 16 years
the cumulative incidence was 2.5% [95% CI: 2.3–2.8%], 2.4% [95%CI: 2.2-2-6%], and 3.8%
[95% CI: 3.4-4-2%] among children with maternal, paternal, and sibling-to-sibling probands,
respectively. A significantly higher cumulative incidence was observed among siblings-to-sib-
ling probands compared with children of maternal and paternal probands. The relative rate of
VTE was significantly increased among all first-degree relatives compared with the general
population and with the highest estimates found among siblings (SIR of 2.60 [95% CI: 2.38–
2.83], Fig 3).
Furthermore a “dose-response” relationship was observed; the lower the age at diagnosis
of the proband, the higher rate of VTE was observed among first-degree relatives (p-value
for interaction with age< 0.001) (Fig 4). Further, the relative rate of VTE was significantly
increased when the proband was diagnosed at a young age ( 50 years of age, p-value for inter-
action<0.001) (S3 Table).
Fig 1. Flowchart over selection process. Study cohort, was compromised of patients discharged with VTE
from 1978–2012. The cohort was further divided into probandship, and further into children of maternal and
paternal proband and sibling to sibling probands.
doi:10.1371/journal.pone.0169055.g001
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Sensitivity analyses
In an analysis exploring the rate of VTE in first-degree relatives with one or several probands
previously hospitalized with VTE the highest estimate was observed among first-degree rela-
tives with more than one VTE proband (Fig 5). Lastly, examining the rate of VTE among
spouses revealed a significantly increased relative rate of VTE among spouses compared with
the general population (Fig 5).
Discussion
In this nationwide cohort-study covering a thirty-four year time period, we investigated the
rate of VTE among first-degree relatives to individuals previously diagnosed with VTE. Our
Table 1. Baseline characteristics of probands, divided into maternal, paternal and sibling probands.
Variables Maternal proband N = 38,862 Paternal proband N = 35,355 Sibling proband N = 18,526
Patient characteristic
Median age (IQR) 64 (49–74) 64 (54–73) 39 (31–46)
Males (%) 0 (0) 35,355 (100) 8,467(45.7)
Index event
DVT (%) 26,035 (70.0) 23,977 (67.8) 14,205 (76.6)
PE (%) 12,827 (30.0) 11,378 (32.2) 4,321 (23.4)
Comorbidities (%)
Stroke 2,304 (5.93) 2,529 (7.15) 311 (1.68)
Acute myocardial infarction 1,890 (4.86) 3,346 (9.46) 247 (1.34)
Atrial fibrillation 2,512 (6.46) 3,021 (8.54) 218 (1.18)
Ischemic heart disease 5,082 (13.08) 6,620 (18.72) 691 (3.73)
Vascular disease 1,431 (3.68) 1,635 (4.62) 199 (1.07)
Artery disease 454 (1.17) 4,41 (1.25) 188 (1.01)
Chronic heart failure 3,108 (8.0) 3,446 (9.75) 361 (1.95)
Chronic kidney disease 801 (2.06) 1,150 (3.25) 314 (1.69)
Liver disease 691 (1.78) 716 (2.03) 331 (1.79)
Hypertension 1,717 (30.15) 9,953 (28.15) 1,551 (8.37)
Diabetes mellitus 3,358 (8.64) 3,343 (9.46) 640 (3.46)
Cancer 7,864 (20.24) 6,982 (19.75) 1,305 (7.04)
COPD 3,995 (10.28) 3,470 (9.81) 394 (2.13)
Concomittant medication
ADP-receptor blockers 9,437 (23.76) 9,465 (26.77) 1,058 (5.71)
Aspirin 9,180 (23.62) 9,362 (26.48) 1,057 (5.71)
Diuretics 13,615 (35.03) 8,829 (24.97) 1,931 (10.42)
Loop 9,879 (25.42) 7,097 (20.07) 1,372 (7.42)
Beta-blockers 9,193 (23.66) 7,614 (21.54) 1,867 (10.08)
Calcium channel blockers 8,090 (20.82) 7,364 (20.83) 1,063 (5.74)
Renin-angiotensin system blockers 9,269 (23.85) 8,794 (24.87) 1,423 (7.68)
Vasodilators 30 (0.08) 34 (0.10) 17 (.0.09)
Digoxin 1,798 (4.63) 1,977 (5.59) 82 (0.44)
Oral anticoagulation 2,919 (7.51) 3,442 (9.74) 1,172 (6.33)
Heparin 533 (1.37) 383 (1.08) 288 (1.55)
Statin 5,861 (15.08) 5,715(16.16) 856 (4.62)
Antipsychotics 4,575 (11.77) 2,535 (7.17) 1,822 (9.83)
Non-steroidal anti-inflammatory drugs 28,449 (73.21) 24,020 (67.94) 12,965 (69.98)
Anti-diabetics without insulin 2,272 (5.85) 2,240 (6.34) 449 (2.42)
Anti-diabetics with insulin 111 (2.60) 1,003 (2.84) 323 (1.74)
doi:10.1371/journal.pone.0169055.t001
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main findings revealed a significantly increased rate of VTE among first-degree relatives com-
pared with the Danish background population irrespective of whether the proband was a
mother, father, or a sibling albeit with the highest estimates found among siblings. Notewor-
thy, when the proband had VTE in a young age the relative rates of VTE in first-degree rela-
tives were significantly higher.
Findings in relation to other studies
Results from this study, is consistent with those reported from other studies, that a family his-
tory of VTE is associated with a two- to threefold increased risk of VTE in first-degree rela-
tives, with the risk increasing according to age at diagnosis for the proband and number of
Table 2. Baseline characteristics of first-degree relatives divided into children of maternal or paternal probands and siblings to sibling probands.
Variables Children of maternal proband
N = 70,767
Children of paternal proband
N = 66,065
Sibling to sibling
N = 29,183
Patient characteristic
Median age (IQR) 35 (21–44) 34 (23–42) 38 (30–45)
Males (%) 37,403 (52.9) 34,848 (52.8) 15,487 (53.1)
Comorbidities (%)
Stroke 286 (0.40) 192 (0.29) 156 (0.53)
Acute myocardial infarction 260 (0.37) 150 (0.23) 152 (0.52)
Atrial fibrillation 215 (0.30) 156 (0.24) 133 (0.46)
Ischemic heart disease 748 (1.06) 492 (0.74) 441 (1.51)
Vascular disease 104 (0.15) 68 (0.10) 73 (0.25)
Artery disease 36 (0.05) 20 (0.03) 16 (0.05)
Chronic heart failure 307 (0.43) 225 (0.34) 153 (0.52)
Chronic kidney disease 210 (0.30) 176 (0.27) 108 (0.37)
Liver disease 245 (0.35) 191 (0.29) 145 (0.50)
Hypertension 2,754 (3.89) 1721 (2.61) 1,420 (4.87)
Diabetes mellitus 1,210 (1.71) 935 (1.42) 641 (2.20)
Cancer 1,101 (1.56) 930 (1.41) 499 (1.71)
COPD 481 (0.68) 341 (0.52) 261 (0.89)
Concomitant medication
ADP-receptor blockers 1,205 (1.70) 798 (1.21) 839 82.60)
Aspirin 1245 (1.76) 830 (1.26) 763 (2.61)
Diuretics 3,179 (4.49) 2092 (3.17) 1,672 (5.73)
Loop 1,043 (1.47) 740 (1.12) 608 (2.08)
Beta-blockers 3,708 (5.24) 2,983 (4.52) 1,894 (6.49)
Calcium channel blockers 1,763 (2.49) 1,129 (1.71) 875 (3.00)
Renin-angiotensin system blockers 2,654 (3.75) 1,667 (2.52) 1,424 (4.88)
Vasodilators 6 (0.01) 6 (0.01) <3(0.01)
digoxin 80 (0.11) 45 (0.07) 40 (0.14)
Oral anticoagulation 246 (0.35) 168 (0.25) 155 (0.53)
Heparin 69 (0.10) 64 (0.10) 50 (0.19)
Statins 1702 (2.41) 1,030 (1.56) 1,031 (3.53)
Antipsychotics 2,462 (3.48) 1,967 (2.98) 1,376 (4.72)
Non-steroidal anti-inflammatory
drugs
31,589 (44.64) 2,8591(43.28) 1,6523 (56.58)
Anti-diabetics without insulin 659 (0.93) 459 (0.69) 437 (1.50)
Anti-diabetics with insulin 552 (0.78) 467 (0.71) 309 (1.06)
doi:10.1371/journal.pone.0169055.t002
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affected probands. [17, 19, 20, 22, 29, 30, 37] However, some of these studies have been small,
and have been prone to recall and selection bias. [17, 22, 29] Zoller et al, have conducted sev-
eral large cohort studies on a Swedish population, but these studies have been limited by the
lack of information on, and control for, important risk factors for VTE. [19, 20, 30]
Similarly to Zoller et al, we observed an increased risk of VTE when the proband was a
father, mother or a sibling. [19, 30] Interestingly, the highest relative risk of VTE was observed
when the proband was a sibling. This association has not been described previously, and can
possibly be explained by siblings sharing more of the same environmental risk factors. Another
important observation was that the highest estimates were observed among first-degree rela-
tives with more than one proband, regardless of type of probandship. Other studies have
shown a similar trend [17–20], which emphasizes the importance of considering the highly
increased risk associated with having more than one proband.
Additionally, we observed a reverse relationship between the rate of VTE and age at VTE
diagnosis for the proband, other studies have reported a similar trend, and this may advocate
for a genetic component. [20, 21, 30] The relationship between age at diagnosis of the proband,
Fig 2. Cumulative incidence of VTE among first-degree relatives. Absolute risk of VTE among first-degree relatives to patients previously
hospitalized with VTE. The numbers below the figure represents the number of patients still at risk, i.e. patients who are still in the study.
doi:10.1371/journal.pone.0169055.g002
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and the increased rate observed among first-degree relatives with more than one affected pro-
band, suggests that the disease follow complex traits, rather than following classical Mendelian
genetics with monogenic traits, possibly caused by an additive genetic effect or by gene-gene
interactions. [19, 38, 39] As of today, 17 genes have been associated with genetic variations
increasing the risk of VTE. [9] However, common polymorphisms have been estimated to
only account for 5% of VTE heritability [9] and thus further studies on common and especially
rare variants are needed to disentangle the genetic structure of VTE heritability. [9]
Zoller et al. investigated the familial risk of VTE among adoptees, and found that adoptees
with affected non-biological parents did not have a significantly increased risk of VTE,.[40]
However, it was found that adoptees with affected biological parents had a significantly
increased risk of VTE.[40] The study suggested that genetic factors contributed more to the
risk of VTE than environmental factors.[40] We observed lower estimates of VTE risk among
spouses than among first-degree relatives as compared with the general population, suggesting
that the genetic component plays a large role compared with environmental factors.[40] To
further investigate to which extend familial environment influences the rate of VTE, we aimed
at performing an analysis of the rate of VTE among adopted children with adoptive parents
having VTE. However, due to a sparse number of events this analysis was not feasible.
Clinical implications
Results from this study will help physicians in identifying high-risk patients by assessing family
history of venous thrombosis. It is important for the clinical practice to be able to identify
high-risk patients that could potentially benefit primary prophylactic anticoagulation treat-
ment in situations that are under normal circumstances considered low risk [8, 41]. However,
it is unknown in which situations primary prophylaxis can be justified, and further research is
needed to clarify this. Secondary prophylaxis can however not be justified, as a family history
with VTE has not been associated with an increased risk of recurrent VTE. [8]
Strengths and limitations
Family aggregation studies provides the basis for the investigation of both genetic and envi-
ronmental risk factors in families [37]. By using the Danish nationwide registries, it was
Fig 3. Standardized incidence ratios (SIRS) of VTE among first-degree relatives. Relative rate of VTE among first-degree relatives to patients
with VTE. The reference is the general population. CI = confidence interval. *Adjusted for age, sex and calendar year. ^Adjusted for age, sex,
calendar year, comorbidities, and concomitant medication.
doi:10.1371/journal.pone.0169055.g003
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possible to include an unselected cohort of patients, with a great variety of comorbidities.
[31, 42] It was possible to include a large study population, which provided robust estimates
for the relative risks. Furthermore, the registration of variables in the utilized registries has
been associated with high validity. [31–33, 42] As of limitations, the diagnosis of VTE has
been associated with a positive predictive value of 75%, however this misclassification is
likely the same for all groups being investigated. [43] Another limitation to this study is the
lack of information on certain risk factors for VTE, such as known thrombophilia, BMI,
smoking, use of oral contraceptives, use of hormonal therapy, and alcohol use, which were
not readily available from the registries. Thus it was not possible to control for these poten-
tial confounders. Lastly, because of the observational study design, this study is based on
associations and thus cannot comment on the causal relationship between family history
and risk of VTE. Furthermore, the influence on social heritability was not investigated,
which provides basis for future research.
Fig 4. Standardized incidence ratios (SIRS) of VTE among first-degree relatives. Relative rate of VTE among first-degree relatives to patients with
VTE. The risk is shown according to the age of diagnosis of the proband, here divided into age groups of the proband. The reference is the general population.
CI = confidence interval. *Adjusted for age, sex and calendar year. ^Adjusted for age, sex, calendar year, comorbidities, and concomitant medication.
doi:10.1371/journal.pone.0169055.g004
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Conclusion
This study is one of the largest cohort studies to describe the familial clustering of VTE. It was
found that a family history of VTE was associated with an increased rate of VTE among first-
degree relatives. The highest rates were observed when the proband was a sibling, when having
more than one proband and when the proband was diagnosed with VTE in a young age.
Results from this study have provided robust estimates for the risk of VTE among first-degree
relatives, and emphasizes the importance of considering family history of VTE when identify-
ing high-risk patients.
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